CNS Pharmaceuticals, Inc. Legal Fees
CNS Pharmaceuticals, Inc. (CNSP) reported Legal Fees of $100.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2024-04-01
- CNS Pharmaceuticals, Inc. legal fees for fiscal 2023 was $100.00K, a 0.00% change from fiscal 2022.
- CNS Pharmaceuticals, Inc. legal fees for fiscal 2022 was $100.00K.
| Period end | Legal Fees 12 month |
|---|---|
| 2023-12-31 | $100.00K 10-K · filed 2024-04-01 |
| 2022-12-31 | $100.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |